Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity.
Pediatr Obes
; 14(1)2019 01.
Article
em En
| MEDLINE
| ID: mdl-30257076
ABSTRACT
BACKGROUND:
Children with obesity are more likely to suffer gastroesophageal reflux disease, requiring acid-suppression therapy with proton pump inhibitors (PPIs) and no guidelines regarding dosing.OBJECTIVE:
To prospectively evaluate lean-body-weight-based (LBW) dosing of the PPI pantoprazole for children with and without obesity.METHODS:
Methods:
Sixty-two children (6-17 years) received a one-time oral dose of liquid pantoprazole (1.2 mg kg-1 LBW). Plasma pantoprazole concentrations were measured at 10 time points over 8 h and pharmacokinetic (PK) profiles generated using non-compartmental techniques, in order to compare PK parameters of interest between children with and without obesity, while accounting for CYP2C19 genotype.RESULTS:
Adjusted for milligram-per-kilogram total body weight (TBW) pantoprazole received, apparent drug clearance (CL/F) was reduced 50% in children with vs. without obesity (p=0.03). LBW-based dosing compensated for this reduction in CL/F (p = 0.15).CONCLUSION:
To achieve comparable systemic PPI exposures for children with and without obesity, we recommend using LBW, rather than TBW-based dosing for pantoprazole.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Peso Corporal
/
Refluxo Gastroesofágico
/
Inibidores da Bomba de Prótons
/
Obesidade Infantil
/
Pantoprazol
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article